Apr 30, 2013, 04.43 PM | Source: PTI
Drug maker Aurobindo Pharma Ltd today said the company has received final approval from the US health regulator to manufacture and market Quinapril tablets in the American market.
The company has received the approval from the US Food and Drug Administration (USFDA) to manufacture the drug, which is indicated for the treatment of hypertension and falls under the cardiovascular (CVS) therapeutic category, in strengths of 5mg, 10mg, 20mg and 40mg (ANDA 202725), it said in a release.
The market size of the product is estimated to be USD 49 million for the 12 months ended September 2012, according to IMS, it said. The product has been approved out of Unit VII (SEZ) formulations facility in Hyderabad, it said. Aurobindo now has a total of 188 ANDA approvals (161 final approvals including 4 from Aurolife Pharma LLC and 27 tentative approvals) from USFDA, the release added. Shares of Aurobindo were quoting at Rs 187.70 apiece, down 2.24 per cent, in the late afternoon trade on the BSE.
Aurobindo Pharm stock price
On February 12, 2016, Aurobindo Pharma closed at Rs 659.60, up Rs 18.00, or 2.81 percent. The 52-week high of the share was Rs 891.50 and the 52-week low was Rs 490.50.
The company's trailing 12-month (TTM) EPS was at Rs 26.48 per share as per the quarter ended December 2015. The stock's price-to-earnings (P/E) ratio was 24.91. The latest book value of the company is Rs 94.54 per share. At current value, the price-to-book value of the company is 6.98.
Buy Aurobindo Pharma;target of Rs 940: Axis Securities
Axis Securities is bullish on Aurobindo Pharma has
Buy Aurobindo Pharma; target of Rs 905: Emkay
Emkay is bullish on Aurobindo Pharma and has recom
Aurobindo Pharma gets USFDA nod for Levofloxacin injection
The approval is for Levofloxacin in 5 percent Dext
Aurobindo Pharma receives USFDA approval for Levofloxacin in Dextrose Injection
Aurobindo Pharma has received final approval from
Like Aurobindo Pharma, Glenmark Pharma: SP Tulsian
SP Tulsian of sptulsian.com likes Aurobindo Pharma
Where will funding for recovery come from, asks Ajay Srivastava
Ajay Srivastava, CEO of Dimensions Consulting says
Sun Pharma to ask FDA in Q1 FY17 for Halol re-inspection
Hold Torrent Pharma; target of Rs 1560: Religare
Religare has recommended hold rating on Torrent Ph